Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
09/2002
09/17/2002CA2187908C Non-splicing variants of gp350/220
09/17/2002CA2095534C Avirulent microbes and uses therefor
09/17/2002CA2038667C Process for the preparation of mannosyl teicoplanin derivatives and mannosyl teicoplanin aglycone
09/17/2002CA2020431C Aqueous liquid eyedrop composition
09/17/2002CA2014662C Anti-virals
09/15/2002CA2373454A1 Recombinant infectious laryngotracheitis virus vaccine
09/12/2002WO2002070748A2 Response of dendritic cells to a diverse set of pathogens
09/12/2002WO2002070669A2 Secreted proteins
09/12/2002WO2002070654A2 Peptide deformylase inhibitors
09/12/2002WO2002070653A2 Peptide deformylase inhibitors
09/12/2002WO2002070563A2 Nuclear hormone receptor ligand binding domain
09/12/2002WO2002070562A2 Nuclear hormone receptor ligand binding domain
09/12/2002WO2002070561A2 Nuclear hormone receptor ligand binding domain
09/12/2002WO2002070560A2 Nuclear hormone receptor ligand binding domain
09/12/2002WO2002070559A2 Nuclear hormone receptor ligand binding domains
09/12/2002WO2002070558A2 Nuclear hormone receptor ligand binding domain
09/12/2002WO2002070557A2 Nuclear hormone receptor ligand binding domain
09/12/2002WO2002070547A1 Template-fixed peptidomimetics with antimicrobial activity
09/12/2002WO2002070541A2 Peptide deformylase inhibitors
09/12/2002WO2002070540A2 Peptide deformylase inhibitors
09/12/2002WO2002070537A2 Fusidic acid derivatives
09/12/2002WO2002070533A2 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
09/12/2002WO2002070518A1 Polymorphic and other crystalline forms of cis-ftc
09/12/2002WO2002070516A2 Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
09/12/2002WO2002070515A2 Chromane derivatives, process for their preparation and their use as antitumor agents
09/12/2002WO2002070511A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
09/12/2002WO2002070499A2 Prodrugs derivatives of the ascorbic acid suitable to the passage of the hematoencephalic barrier
09/12/2002WO2002070491A1 Nitrogenous heteroaromatic ring derivative having hiv integrase inhibitory activity
09/12/2002WO2002070487A1 Substituted quinolinecarboxamides as antiviral agents
09/12/2002WO2002070486A1 Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity
09/12/2002WO2002070479A1 N-4-piperidinyl compounds as ccr5 modulators
09/12/2002WO2002070470A2 Benzophenones as inhibitors of reverse transcriptase
09/12/2002WO2002070464A2 Hydrazones and their therapeutic use
09/12/2002WO2002070455A1 Malic acid addition salts of terbinafine
09/12/2002WO2002070016A2 Catecholate beta-lactam conjugates, method for producing the same and the use thereof
09/12/2002WO2002070006A2 Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
09/12/2002WO2002070004A2 Papillomavirus vaccines
09/12/2002WO2002070003A1 Altered peptide ligands
09/12/2002WO2002070002A2 Methods for regulation of immune responses to conditions involving mediator-induced pathology
09/12/2002WO2002069999A1 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
09/12/2002WO2002069991A1 Bacterial translocation inhibitor and method of inhibiting bacterial translocation
09/12/2002WO2002069989A2 Aquatic animal treatment method and composition containing pimenta extract
09/12/2002WO2002069979A2 Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
09/12/2002WO2002069977A1 Use of certain steroids for treatment of blood cell deficiencies
09/12/2002WO2002069970A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
09/12/2002WO2002069954A1 Composition and methods for the treatment and prevention of bovine mastitis
09/12/2002WO2002069949A2 Combination therapy for reduction of toxycity of chemotherapeutic agents
09/12/2002WO2002069948A1 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
09/12/2002WO2002069943A2 Use of pyrimidine nucleosides and/or the prodrugs thereof for combating the side-effects of haart (highly active anti-retroviral therapy) and other anti-viral therapies
09/12/2002WO2002069939A2 Taste masked pharmaceutical compositions
09/12/2002WO2002069930A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues
09/12/2002WO2002069887A2 Virucidal compositions
09/12/2002WO2002069799A1 Method of predicting stroke evolution utilising mri
09/12/2002WO2002069691A2 Immunogenic hiv peptides for use as reagents and vaccines
09/12/2002WO2002053178A3 Immunogenic complex comprising ribosomes
09/12/2002WO2002051865A3 Proteinic antigens inducing antibodies neutralising hiv virus
09/12/2002WO2002050030A3 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
09/12/2002WO2002026717A3 Hydroxy acid integrin antagonists
09/12/2002WO2002022680A3 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine)
09/12/2002WO2002018605A3 Anti-microbial agents
09/12/2002WO2002014369A3 Human kininogen d5 domain polypeptides and their use
09/12/2002WO2002012346A3 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line
09/12/2002WO2001089558A3 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
09/12/2002WO2001089520A3 Dehydroascorbic acid formulations and uses thereof
09/12/2002WO2001083529A3 Immunoadhesin for the prevention of rhinovirus infection
09/12/2002WO2001077335A3 Listeria monocytogenes genome, polypeptides and uses
09/12/2002WO2001071346A3 Binding compounds for cc chemokine receptor 5 and methods for identifying them
09/12/2002WO2001068078A3 Immunostimulatory polynucleotide sequences for use in suppressing hepatitis virus infection
09/12/2002WO2001047562A3 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
09/12/2002WO2001040232A9 Chlorophyll and bacteriochlorophyll esters, and their preparation
09/12/2002WO2001019852A3 Methods of peptide preparation
09/12/2002WO2001016183A9 Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
09/12/2002WO2001015680A9 Composition for treatment of infections of humans and animals
09/12/2002WO2001010901A9 Antimicrobial histone h1 compositions, kits, and methods of use thereof
09/12/2002WO2001003729A3 Recombinant envelope vaccine against flavivirus infection
09/12/2002US20020129395 Compositions to identify swine genetically resistant to F18 E. coli associated diseases
09/12/2002US20020128444 Controling abberant inflamatory response; obtain animal, incubate with modulator of inflammation, monitor animal for adjustment in inflammatory response
09/12/2002US20020128442 Human proteins STAM2a and STAM2b, and cDNAs encoding these molecules
09/12/2002US20020128437 Polypeptide for use in the detection of bactericides and prevention, detect and treatment of infections
09/12/2002US20020128436 Therapeutic composition for use in the treatment of autoimune and rheumatic diseases
09/12/2002US20020128310 Medical composition and use thereof for the manufacture of a topical barrier formulation, a uv-radiation absorbing formulation, or an antiviral, antifungal, or antiinflammtory formulation
09/12/2002US20020128307 Tetramic acid-type compounds isolated from a CCR-5 active complex produced by fermentation under controlled conditions of a biologically pure culture of the microorganism, Chaetomium globosum Kunze
09/12/2002US20020128306 Programmed cell death; expansion of hematopoietic cells, for prolonging viability of an organ for transplantation, and maintaining viability of cell lines used in bioproduction
09/12/2002US20020128283 Process improvement in the preparation of (4R, 5S, 6S)-3-[[(2R,3R)-2-[[[(S)-2-amino-3-methyl-1-oxobutyl]amino]methyl]tetrahydro-3-furanyl]thio]-6-[(R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
09/12/2002US20020128271 N-benzenesulfonyl l-proline compounds as bradykinin antagonists
09/12/2002US20020128263 Treatment or prevention of mGluR5 receptor mediated disorders.
09/12/2002US20020128262 Styrylbenzodiazepines
09/12/2002US20020128254 Antibiotics, bactericides
09/12/2002US20020128251 Novel formulation
09/12/2002US20020128250 Modulating the expression of a gene
09/12/2002US20020128213 Sixteen-membered macrolide compounds
09/12/2002US20020128212 Ring contracted Leucomycin analogs, for treating bacterial infections
09/12/2002US20020128210 Treating a fungal or yeast infection such as with betulin, allobetulin, and lupeol
09/12/2002US20020127694 2786, a novel human aminopeptidase
09/12/2002US20020127692 Enzymatic polypeptide for use in the treatment of viral infections, cancer, inflammation, brain disorders and asthma
09/12/2002US20020127682 Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
09/12/2002US20020127675 Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
09/12/2002US20020127668 Polypeptide for use in the diagnosis and treatment of cancer, nervous system and vessicular transport disorders
09/12/2002US20020127647 ATP-binding cassette transporter-like molecules and uses thereof
09/12/2002US20020127605 Cyclophilin compound for use in the treatment of infections, nervous system, skin, ischemic and vision disorders
1 ... 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 ... 1798